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Detection of Left Ventricular Thrombus by Delayed-
Enhancement Cardiovascular Magnetic Resonance
Prevalence and Markers in Patients With Systolic Dysfunction
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Anna Lisa Crowley, MD,*† Rhoda Brosnan, MD,*† Olga G. James, MD,*§ Manesh R. Patel, MD,*†
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Durham, North Carolina; and Brentwood, Tennessee
Objectives This study sought to assess the prevalence and markers of left ventricular (LV) thrombus among patients with
systolic dysfunction.
Background Prior studies have yielded discordant findings regarding prevalence and markers of LV thrombus. Delayed-
enhancement cardiovascular magnetic resonance (DE-CMR) identifies thrombus on the basis of tissue character-
istics rather than just anatomical appearance and is potentially highly accurate.
Methods Prevalence of thrombus by DE-CMR was determined in 784 consecutive patients with systolic dysfunction (left
ventricular ejection fraction [LVEF] 50%) imaged between July 2002 and July 2004. Patients were recruited
from 2 separate institutions: a tertiary-care referral center and an outpatient clinic. Comparison to cine-
cardiovascular magnetic resonance (CMR) was performed. Follow-up was undertaken for thrombus verification
via pathology evaluation or documented embolic event within 6 months after CMR. Clinical and imaging param-
eters were assessed to determine risk factors for thrombus.
Results Among this at-risk population (age 60 14 years; LVEF 32  11%), DE-CMR detected thrombus in 7% (55 patients)
and cine-CMR in 4.7% (37 patients, p 0.005). Follow-up was consistent with DE-CMR as a better reference stan-
dard than cine-CMR, including 100% detection among 5 patients with thrombus verified by pathology (cine-CMR, 40%
detection), and logistic regression analysis testing the contributions of DE-CMR and cine-CMR simultaneously, which
showed that only the presence of thrombus by DE-CMR was associated with follow-up end points (p 0.005). Cine-
CMR generally missed small intracavitary and small or large mural thrombus. In addition to traditional indices such
as low LVEF and ischemic cardiomyopathy, multivariable analysis showed that increased myocardial scarring, an ad-
ditional parameter available from DE-CMR, was an independent risk factor for thrombus.
Conclusions In a broad cross section of patients with systolic dysfunction, thrombus prevalence was 7% by DE-CMR and in-
cluded small intracavitary and small or large mural thrombus missed by cine-CMR. Prevalence increased with
worse LVEF, ischemic etiology, and increased myocardial scarring. (J Am Coll Cardiol 2008;52:148–57)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.041p
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ratients with heart failure are at increased risk for throm-
oembolic events that may result in major clinical sequelae.
eft ventricular (LV) thrombus provides a substrate for
vents and a rationale for anticoagulation (1). However,
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einsaft). Drs. Kim and Judd are inventors of a U.S. patent on delayed-enhancement
agnetic resonance imaging, which is owned by Northwestern University.a
Manuscript received September 6, 2007; revised manuscript received February 6,
008, accepted March 4, 2008.rior echocardiography studies have yielded discordant re-
ults regarding thrombus prevalence. Among populations
ith similar degrees of systolic dysfunction, studies have
eported over a 20-fold difference in prevalence, ranging
rom 2.1% to 50% (2–4). Moreover, when thrombus is
dentified, discordant findings have been reported concern-
ng the risk of future embolic events (4–7). One potential
eason for these disparate findings may relate to limitations
f echocardiography, which has been the predominant
odality used to identify LV thrombus. Prior echocardiog-
aphy studies have reported significant interobserver vari-
bility in diagnosing LV thrombus (8). Others have shown
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July 8, 2008:148–57 Detection of LV Thrombus by DE-CMRhat up to 46% of echocardiograms may be diagnostically
nconclusive for thrombus (9). As the benefits of anti-
oagulation for treatment of thrombus are counterbalanced
y hemorrhagic risk, patient management and outcome may
e improved by a better understanding of the prevalence and
isk factors for LV thrombus.
Cardiovascular magnetic resonance (CMR) provides
igh-resolution images of anatomy with improved repro-
ucibility as compared with echocardiography (10).
owever, a simple anatomical approach may be relatively
nsensitive for thrombus because thrombus may be indistin-
uishable from surrounding myocardium (11). Delayed-
nhancement cardiovascular magnetic resonance (DE-
MR) using gadolinium contrast has been well validated as
means of characterizing viable and infarcted myocardium
n the basis of contrast uptake patterns (12). More recently,
his technique has also shown promise as a sensitive method
or detecting LV thrombus (13,14); DE-CMR differenti-
tes thrombus from surrounding myocardium as thrombus
s avascular and thus characterized by an absence of contrast
ptake (13,14). In studies of selected groups, DE-CMR
dentified thrombus not detected by anatomical imaging
sing either cine-CMR or echocardiography (13,14). At
resent, however, DE-CMR has not been used to study
hrombus in a general, unselected population at risk for
hrombus, such as patients with systolic dysfunction. The
ims of the current study were 3-fold: first, to assess the
revalence of thrombus using DE-CMR among a broad
ross section of patients with systolic dysfunction; second, to
ompare DE-CMR to anatomical imaging using cine-
MR; and third, to determine predisposing risk factors for
V thrombus formation by evaluating numerous clinical
nd imaging parameters.
ethods
opulation. The study population consisted of consecutive
atients with systolic dysfunction who underwent cine- and
E-CMR during a single imaging session between July
002 and July 2004. Patients were recruited from the Duke
ardiovascular Magnetic Resonance Center (Durham,
orth Carolina), a tertiary-care referral center, or the
ashville Cardiovascular Magnetic Resonance Institute
Brentwood, Tennessee), a clinical outpatient facility. Sys-
olic dysfunction was defined as a left ventricular ejection
raction (LVEF) below 50% measured quantitatively on
ine-CMR. Patients were referred to CMR most commonly
or evaluation of myocardial viability, assessment of myo-
ardial infarction, or evaluation of scar patterns in cases of
uspected cardiomyopathy. Institutional review board ap-
roval was obtained at both participating sites; all patients
rovided written informed consent.
On the day of the CMR procedure, a complete medical
istory including cardiac risk factors, medication regimen, and
nformation regarding prior coronary revascularization, myo-
ardial infarction, and thromboembolic events, was obtained to mssess potential predictors of
hrombus. Additionally, clinical
ecords were reviewed including
rior X-ray coronary angiography
esults, and established criteria
ere used to classify the etiology of
ystolic dysfunction as ischemic or
onischemic: patients were con-
idered to have ischemic cardio-
yopathy if there was angio-
raphically significant disease
70% stenosis of a major epicar-
ial artery or 50% of the left
ain artery [15]), history of bi-
marker proven myocardial infarc-
ion, or evidence of ischemia on
linical stress testing (16). All
ther patients were classified as
aving nonischemic cardiomyopathy. The majority of patients
86%) had previously undergone coronary angiography.
linical follow-up and validation of imaging. Follow-up
as performed prospectively in all patients to provide data
egarding the choice of a truth standard for the diagnosis of
V thrombus. Specifically, all records were carefully re-
iewed in patients who had direct inspection and pathology
valuation of the left ventricle (i.e., patients who underwent
eart transplantation, LV aneurysmectomy, or post-mortem
ecropsy) within 6 months after CMR without intervening
vents. Additionally, all specimens were re-examined thor-
ughly by a cardiovascular pathologist (C.S.). Follow-up
as also performed for identification of clinical embolic
vents that were highly suggestive of the presence of LV
hrombus. These events consisted of a documented cerebro-
ascular accident (CVA) or transient ischemic attack (TIA)
hat prompted the initial clinical workup or occurred within
months after CMR. A relatively short follow-up time of 6
onths was chosen to increase the likelihood that clinical
vents were related to findings at the time of imaging.
linical information was obtained via: 1) telephone inter-
iew with the patient, or, if deceased, with family members;
) contact with the patient’s physician; and 3) hospital
ecords. Death was not considered evidence of LV throm-
us unless directly linked to a cerebrovascular embolic event.
mage acquisition. MAGNETIC RESONANCE IMAGING.
.5-T clinical scanners (Siemens Sonata, Siemens, Malvern,
ennsylvania) with phased-array coil systems were used. In
ll patients, CMR consisted of 2 components as previously
escribed (17). Briefly, cine-CMR was performed for ana-
omical and functional assessment using a steady-state
ree-precession sequence (repetition time, 3.0 ms; echo
ime, 1.5 ms; in-plane spatial resolution, 1.7  1.4 mm;
emporal resolution, 35 to 40 ms), and DE-CMR was
erformed for tissue characterization using a segmented
nversion-recovery sequence (18) (in-plane spatial reso-
ution, 1.8  1.3 mm; temporal resolution, 160 to 200
Abbreviations
and Acronyms
CMR  cardiovascular
magnetic resonance
CVA  cerebrovascular
accident
DE-CMR  delayed-
enhancement
cardiovascular magnetic
resonance
LV  left ventricle/
ventricular
LVEF  left ventricular
ejection fraction
TI  inversion time
TIA  transient ischemic
attacks) 10 min after contrast administration (gadoverset-
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Detection of LV Thrombus by DE-CMR July 8, 2008:148–57mide, 0.15 mmol/kg). Cine- and DE-CMR images were
btained in matching short- and long-axis planes (slice
hickness, 6 mm). Short-axis images were acquired every
cm (gap, 4 mm) throughout the entire LV. Long-axis
mages were obtained in standard 2-, 3-, and 4-chamber
rientations.
For DE-CMR, inversion times were adjusted in the stan-
ard fashion to null viable myocardium (17). Additionally, for
mages with filling defects that were suspicious for thrombus,
erial imaging was performed at 10-min intervals for at least 30
in post-contrast to verify absence of contrast uptake (19).
E-CMR thrombus identification and “long-inversion
ime (TI)” imaging. Thrombus was diagnosed on DE-
MR as an LV mass with post-contrast inversion-recovery
haracteristics consistent with avascular tissue (14,19). Typ-
cally, this meant that thrombus was easily identified as a
ow signal-intensity mass surrounded by high signal-
ntensity structures such as cavity blood and/or hyperen-
anced myocardial scar (14). However, prior experience at
ur center has shown that occasionally the diagnosis may be
ess straightforward. With conventional DE-CMR, both
iable myocardium and thrombus will appear relatively dark
nd may be difficult to distinguish from one another.
lthough contrast uptake is low in viable as compared with
nfarcted myocardium, it is not zero, as is the case with
vascular tissue such as thrombus. Thus, using standard
E-CMR with an inversion time tailored to null viable
yocardium, thrombus may not appear homogeneously
lack but instead have an “etched” appearance (19) with a
lack border and a central gray zone, which may complicate
he diagnosis (Fig. 1) (standard DE-CMR). The difference
n contrast uptake between viable myocardium and throm-
us, however, can be used to improve the conspicuity of
hrombus. For the purposes of this study, a modified
E-CMR sequence was designed in which the inversion
ime was increased from that needed to null viable myocar-
ium (approximately 350 ms) to a fixed time of 600 ms,
hich nulls avascular tissue such as thrombus (19). With
his “long inversion time” (long-TI) sequence, regions with
ontrast uptake such as viable myocardium increase in image
ntensity (i.e., appear gray rather than black), thrombus
ppears homogeneously black, and there is improved
hrombus delineation (Fig. 1). Because standard DE-CMR
as necessary for the assessment of myocardial viability and
ong-TI imaging required additional breath-holds, scanner
perators were instructed to perform long-TI DE-CMR
udiciously (31% of patients), when additional imaging
ould clarify the presence or absence of thrombus.
ata analysis. THROMBUS ASSESSMENT. All images were
nterpreted by consensus of 2 experienced readers (both level-3
rained in CMR) who were blinded to subject identifiers and
linical history. A pre-designated third reader was consulted in
ases of interpretive discordance (cine-CMR 1%, DE-CMR
%). Studies were read in random order. Cine- and DE-CMR
ere interpreted independently of each other. bFor DE-CMR, thrombus morphology was classified as
ither mural (if borders were contiguous with adjacent
ndocardial contours) or intracavitary (borders were distinct
rom endocardial contours with protrusion into LV cavity)
6). Thrombus volume was measured quantitatively via
lanimetry. Thrombus location was scored based on adja-
ent myocardial segments using a standard American Heart
ssociation 17-segment LV model. Previously established
riteria (13,19) were used to distinguish thrombus from an
rea of acute myocardial infarction with microvascular
bstruction (20), which may also appear as a filling defect.
n brief, differentiating features included: 1) surrounding
tructures (no-reflow zones should be completely encom-
assed in 3-dimensional space by hyperenhanced myocar-
ium or LV cavity, this is not an absolute finding for
hrombus); 2) appearance (no-reflow occurs within the
yocardium, thrombus can occur in the LV cavity, and
eatures such as protruding structures and abrupt transitions
uggest thrombus); and 3) stability of size on consecutive
E-CMR acquisitions (no-reflow size shrinks from con-
rast fill-in at the periphery, thrombus size is stable).
For cine-CMR, LV thrombus was diagnosed using es-
ablished anatomical criteria (21). Thrombus was defined as
mass within the LV cavity with margins distinct from
entricular endocardium and distinguishable from papillary
uscles, chordae, trabeculations, or technical artifact.
hrombus was excluded based on inspection of both short-
nd long-axis views.
maging markers of thrombus. CMR indices of LV func-
ion, geometry, and scarring were measured to determine
hether these parameters were related to the presence of
hrombus. The LVEF and LV volumes were quantitatively
easured on the basis of end-diastolic and -systolic endo-
ardial contours from the stack of short-axis cine images.
egional wall motion and scarring were assessed on a
tandard 17-segment model using previously described
ethods (17). Regional function on cine-CMR was graded
n a 5-point scale as follows: 0  normal contraction; 1 
ild-to-moderate hypokinesia; 2 severe hypokinesia; 3
kinesia; 4 dyskinesia. Cine-CMR was also scored for the
resence of LV aneurysm, defined as a discrete akinetic or
yskinetic bulge interrupting the normal LV contour in
iastole and systole (22). Regional scarring based on area of
yperenhanced (bright) myocardium on DE-CMR was
raded on a 5-point scale as follows: 0  no hyperenhance-
ent; 1  1% to 25%; 2  26% to 50%; 3  51% to 75%;
 76% to 100%. Global scar size as a percentage of LV
yocardium was calculated by summing the segmental
cores (each weighted by the midpoint of the range of
yperenhancement) and dividing by the total number of
egions (23).
tatistical methods. Normally distributed continuous data
ere expressed as mean  SD and between-group compar-
sons were performed using 2-sample t tests. Comparisons
f non-normally distributed continuous data such as throm-
us volumes were also made using 2-sample t tests after
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July 8, 2008:148–57 Detection of LV Thrombus by DE-CMRnitial logarithmic transformation; results are expressed as
he antilog of the mean and 95% confidence intervals.
hi-square tests were used to compare discrete data be-
ween groups; in those cases in which the expected cell count
as5, the Fisher exact test was used. The McNemar test was
sed to compare the prevalence of thrombus by DE- and
ine-CMR. To test the validity of the imaging techniques for
he presence of LV thrombus, the relationship between
ollow-up end points and the detection of thrombus by DE-
nd cine-CMR, separately and then together, were evaluated
sing logistic regression analysis.
Two separate multivariable approaches were used to
nalyze the value of clinical variables for predicting the
Cine-CMR
Discordance
Concordance
Cine-CMRi -
LV
LA
Lo
Cine-CMRi -
Stat
Lo
LV
LVA
Stt
A
B
Figure 1 DE-CMR Compared With Cine-CMR for Identification o
(A) Typical images from a patient with concordant findings by DE-CMR and cine-CM
views). Pathology (hematoxylin and eosin stain, low power) confirmed the presence
(B) Typical images from a patient with discordant findings by DE-CMR and cine-CM
wall aneurysm, whereas cine-CMR shows no evidence of thrombus (midventricular
histopathology [inset, Masson trichrome stain]). Both patient examples show that
on standard inversion time (TI) DE-CMR, whereas it appears homogeneously black on
magnetic resonance; DE-CMR  delayed-enhancement cardiovascular magnetic res
myocardium.resence of thrombus by DE-CMR. In the first approach, phe best clinical model was identified using stepwise logistic
egression analysis in which all clinical variables in Table 1
ere considered. Then, the incremental value of adding
VEF by cine-CMR and myocardial scarring by DE-CMR
ere assessed using likelihood ratio tests. In the second
pproach, we identified the best overall model in which all
linical and CMR variables were simultaneously considered.
ll statistical tests were 2-tailed; values of p  0.05 were
egarded as significant.
esults
opulation characteristics. The study population was com-
CMR Pathology
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Scar
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Thrombus
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LV
hology-Verified Thrombus
th techniques show an intracavitary thrombus within the LV apex (4-chamber
rombus with organizing features, including prominent collagen and fibrin content.
-CMR demonstrates a large mural thrombus adherent to a left ventricular inferior
axis views). Thrombus was verified by pathology (gross examination [overlay] and
bus may have an etched appearance with a black border and a central gray zone
I imaging. See text for details. Thrombus denoted by yellow arrows. CMR  cardiac
; LA  left atrium; LV  left ventricle; LVA  left ventricular aneurysm; Myo DE-
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Detection of LV Thrombus by DE-CMR July 8, 2008:148–57cteristics of the overall population at the time of CMR are
hown in Table 1. Nearly one-half had a history of a prior
yocardial infarction, and 71% had ischemic cardiomyopathy.
ew patients had a history of a prior cerebrovascular event.
eventeen percent of patients were on chronic warfarin therapy
t the time of CMR; the most common indication was for
trial fibrillation, which included 43% of patients on warfarin.
n 2%, warfarin was used for treatment of suspected LV
aseline Patient Characteristics
Table 1 Baseline Patient Characteristics
Overall (n  784) DE-CM
Clinical parameters
Age (yrs) 60.4 14.1
Male gender 552 (70%)
Atherosclerosis risk factors
Diabetes mellitus 228 (29%)
Hypertension 469 (60%)
Tobacco use 214 (27%)
Hypercholesterolemia 400 (51%)
Prior myocardial infarction
Within 1 month of CMR 133 (17%)
Within 6 months of CMR 147 (19%)
Any history before CMR 377 (48%)
Coronary revascularization 335 (43%)
Percutaneous intervention 208 (27%)
Coronary artery bypass grafting 189 (24%)
Ischemic cardiomyopathy 555 (71%)
Atrial fibrillation or atrial flutter 119 (15%)
Lifetime history of prior cerebrovascular event
CVA 59 (8%)
TIA 38 (5%)
CVA or TIA 92 (12%)
Chronic anticoagulation
Aspirin 511 (65%)
Warfarin 136 (17%)
Thienopyridines 112 (14%)
Heart failure medications
Beta-blocker 511 (65%)
ACE inhibitor 454 (58%)
Angiotensin receptor blocker 85 (11%)
Loop diuretic 320 (41%)
Spironolactone 122 (16%)
Digoxin 189 (24%)
Nitroglycerin 194 (25%)
CMR
LV function and morphology
Ejection fraction (%) 31.8 10.8
Percent LV with akinesia or dyskinesia 24.4 19.2
End-diastolic volume (ml) 207.1 85.9
End-systolic volume (ml) 146.0 80.2
Aneurysm present 101 (13%)
LV scarring
Scar size (% LV) 15.6 14.3
Percent LV with 50% transmural scar 14.2 15.9
umbers in bold indicate p values 0.05.
ACE  angiotensin-converting enzyme; CVA  cerebrovascular accident; CMR  cardiovascula
entricular; TIA  transient ischemic attack.hrombus. 7Cine-CMR showed evidence of advanced systolic dys-
unction. The mean LVEF was 31.8  10.8%. Left ven-
ricular aneurysms were present in 13%. Myocardial scarring
as shown by DE-CMR in 73%; mean scar size was 15.6
4.3% of total LV myocardium.
omparison of DE-CMR with cine-CMR for thrombus
etection. PREVALENCE. Thrombus was identified by DE-
MR in 55 patients, resulting in an overall prevalence of
mbus Present (n  55) DE-CMR Thrombus Absent (n  729) p Value
8.7 10.4 60.4 14.4 0.20
39 (71%) 513 (70%) 0.93
17 (31%) 211 (29%) 0.76
30 (55%) 439 (60%) 0.41
20 (36%) 194 (27%) 0.12
30 (55%) 370 (51%) 0.59
16 (29%) 117 (16%) 0.01
17 (31%) 130 (18%) 0.02
44 (80%) 333 (46%) <0.0001
30 (55%) 302 (41%) 0.06
18 (33%) 190 (26%) 0.28
19 (35%) 170 (23%) 0.06
51 (93%) 504 (69%) 0.0002
6 (11%) 113 (15%) 0.36
5 (9%) 54 (7%) 0.65
2 (4%) 36 (5%) 0.66
7 (13%) 85 (12%) 0.81
37 (67%) 474 (65%) 0.74
14 (25%) 122 (17%) 0.10
8 (15%) 104 (14%) 0.95
35 (64%) 476 (65%) 0.80
33 (60%) 421 (58%) 0.74
6 (11%) 79 (11%) 0.99
25 (45%) 295 (40%) 0.47
9 (16%) 113 (16%) 0.86
13 (24%) 176 (24%) 0.93
18 (33%) 176 (24%) 0.15
6.1 11.0 32.2 10.7 <0.0001
4.8 18.4 23.6 19.2 <0.0001
2.6 120.1 204.5 82.3 0.02
5.6 115.8 143.0 76.2 0.01
15 (27%) 86 (12%) 0.001
4.1 13.7 15.0 14.1 <0.0001
4.5 15.3 13.4 15.6 <0.0001
etic resonance; DE-CMR  delayed-enhancement cardiovascular magnetic resonance; LV  leftR Thro
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July 8, 2008:148–57 Detection of LV Thrombus by DE-CMRo that at Nashville (7.6% vs. 5.3%, p  0.3). A total of 44
f the 55 patients (80%) had thrombus located solely (n 
7) or partially (n  7) in the LV apex.
In comparison, cine-CMR detected thrombus in 37
atients, yielding a prevalence of 4.7%, which was lower
han by DE-CMR (p  0.005) (Table 2). Prevalence of
hrombus by cine-CMR was similar at Duke and Nashville
5.0% vs. 3.8%, p  0.5).
alidation of DE-CMR. Eight patients had direct inspec-
ion and pathology evaluation of the LV either at the time
f cardiothoracic surgery or at necroscopy (aneurysmectomy
5, transplantation 2, necropsy 1). Five had thrombus
erified by pathology, and DE-CMR detected all 5. Con-
ersely, cine-CMR detected only 2 of 5 thrombi (40%).
mong the 3 patients who had thrombus excluded by
athology, neither DE- nor cine-CMR detected thrombus.
epresentative images showing concordance and discor-
ance of findings between imaging techniques with patho-
ogical verification are shown in Figure 1.
For the pre-defined window of 6 months after CMR, 709
atients (90.4%) had complete follow-up for the entire
nterval. Patients with complete follow-up were not differ-
nt from those without follow-up in LVEF or prevalence of
hrombus by DE- or cine-CMR (all, p  NS). Figure 2
tratifies patients according to imaging findings and
ollow-up end points. Patients with thrombus identified by
E-CMR had over a 7-fold higher rate of end points
CVA, TIA, or pathology verification of thrombus) than
atients without thrombus (15.1% vs. 2.1%, p  0.0001),
espite a markedly higher proportion of patients on warfarin
uring the follow-up window (64% vs. 18%, p 0.0001). In
omparison, there was only a 3.0-fold higher rate of end
oints in patients with thrombus identified by cine-CMR
8.6% vs. 2.8%, p  0.06) even though warfarin utilization
cine-CMR thrombus present vs. absent: 60% vs. 19%
arfarin use) was similar to that of patients grouped by
E-CMR thrombus.
Figure 2 also shows that imaging by cine-CMR did not
dd to the information provided by DE-CMR. After
tratification by DE-CMR, the subgroup in whom cine-
MR was positive for thrombus had a similar rate of end
oints to those in whom imaging was negative (p  0.29 in
E-CMR positive group, p  0.72 in DE-CMR negative
roup). Additionally, a bivariate logistic model testing the
ontributions of cine- and DE-CMR simultaneously
howed that only DE-CMR had a significant relationship
etection of Thrombus by CMR
Table 2 Detection of Thrombus by CMR
Cine-CMR Thrombus
DE-CMR Thrombus
TotalPresent Absent
Present 31 6 37*
Absent 24 723 747
Total 55* 729 784v
DE-CMR prevalence: 7.0% (55 of 784) versus cine-CMR prevalence: 4.7% (37 of 784); p 0.005.
Abbreviations as in Table 1.etween the presence of thrombus by imaging and
ollow-up end points (p  0.0001).
hrombus morphology. Table 3 shows that the detection of
hrombus by cine-CMR varied as a function of size and type.
verall, thrombi that were detected by cine-CMR were larger
n volume (4.1 cm3 vs. 1.8 cm3). However, cine-CMR detected
nly 42% (8 of 19) of mural as compared with 64% (23 of 36) of
ntracavitary thrombi identified by DE-CMR, despite the nearly
-fold greater size on average of mural thrombus (4.2 cm3 vs. 2.3
m3). After stratifying by type, only intracavitary thrombus
howed a relationship between detection and size (p 0.003).
linical and structural markers of the presence of throm-
us. UNIVARIABLE MARKERS. Patients with LV thrombus
y DE-CMR did not differ from those without thrombus
n the basis of coronary disease risk factors, atrial arrhyth-
ias, antecedent thromboembolic events, or baseline med-
cation regimen including anticoagulation therapy (Table 1).
atients with thrombus, however, were more likely to have
ad a prior myocardial infarction, have more advanced
ystolic dysfunction and adverse cardiac remodeling by
ine-CMR, and more myocardial scarring by DE-CMR.
The prevalence of thrombus varied according to the etiology
f cardiomyopathy. Figure 3 shows over a 5-fold higher
revalence of thrombus among patients with ischemic com-
ared to those with nonischemic cardiomyopathy (9.2% vs.
.7%, p 0.0002), despite similar mean LVEF (31.8 10.5%
s. 31.7  11.6%, p  0.88) and anticoagulation rate
p  0.72). Figure 3 also shows that although thrombus
revalence increased as LVEF decreased for both ischemic and
onischemic patients, the prevalence was higher in patients
ith ischemic disease for every LVEF group. Interestingly, the
revalence of myocardial scarring was 2-fold higher (86% vs.
3%, p 0.0001) and mean scar size was 3-fold higher (19.4%
s. 6.4% LV, p  0.0001) in patients with ischemic disease,
aralleling the increased prevalence of thrombus.
ULTIVARIABLE MODELS. When considering only tradi-
ional clinical variables, the best model predicting the presence
f thrombus included age, prior myocardial infarction, and
schemic etiology of cardiomyopathy (Fig. 4A). The addition
f LVEF by cine-CMR resulted in an improved model
chi-square increased from 34.99 to 56.43, p  0.0001) (Fig.
B). The addition of myocardial scarring by DE-CMR,
pecifically the percentage of LV more than 50% transmurally
carred, improved the model further (chi-square from 56.43 to
0.95, p  0.03). Interestingly, our second multivariable
pproach by considering all clinical and CMR variables simul-
aneously resulted in the same final model for thrombus
chi-square  60.95). Younger age, prior MI, ischemic car-
iomyopathy, LVEF, and percent LV with 50% transmural
car were all independent markers for thrombus.
Concerning the novel index of myocardial scarring, our
ndings suggest that every 10-point increase in percent
V with transmural scarring would result in a 22%
ncrease in likelihood of thrombus. The independent
alue of myocardial scarring is also illustrated in Figure
4
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Detection of LV Thrombus by DE-CMR July 8, 2008:148–57C, which shows the synergistic nature of considering
oth myocardial contraction and scarring as markers for
hrombus.
iscussion
his is the first investigation to evaluate the prevalence of
hrombus using CMR. There were 3 main findings: 1) among
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the 8 patients who were DE-CMR–positive for thrombus and had clinical event or p
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Table 3 Thrombus Morphology
Thrombus
Overall Cine
Volume (cm3) 2.9 (0.2–35.3)
Type
Intracavitary 36 (65%)
Mural 19 (35%)
Volume according to type
Intracavitary (cm3) 2.3 (0.2–26.7)
Mural (cm3) 4.2 (0.3–53.0)Indices reported as absolute number (percentage) or antilog of mean (95% c
Abbreviations as in Table 1.broad population of patients with systolic dysfunction, 7%
ad thrombus identified by DE-CMR; 2) prevalence of
hrombus was lower by cine- than DE-CMR (p  0.005);
nd 3) myocardial scarring, also detected by DE-CMR, was
dentified as a novel risk factor for thrombus.
Identification of thrombus and associated risk factors has
mportant implications for management of heart failure, a
Cine CMR
thrombus absentnon-ischemic9y
ischemic
ischemic
ischemic
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ased on cine-CMR did not improve differentiation of patients. Details regarding
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ified by DE-CMR (n  55)
p Value (n  31) Cine-CMR  (n  24)
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July 8, 2008:148–57 Detection of LV Thrombus by DE-CMRrowing global epidemic (24). Although large-scale studies
ave found that, overall, patients with systolic dysfunction
ave an increased risk of stroke (25), initiation of anticoag-
lation based solely on clinical characteristics such as LVEF
r post-MI status may decrease thromboembolic events in
ome, at the cost of major bleeding episodes in others (26).
s LV thrombus provides a substrate for thromboembolic
vents and a rationale for anticoagulation, thrombus detec-
ion using DE-CMR holds the potential to improve ther-
peutic decision-making and clinical care of patients with
ystolic dysfunction.
Among the 55 patients with LV thrombus identified by
E-CMR in the current study, 44% (24 of 55) had
ine-CMR examinations that were negative for thrombus.
his finding is consistent with prior studies that have
ompared DE-CMR with anatomical imaging using either
ine-CMR or echocardiography. Mollet et al. (13) reported
hat among 12 patients with thrombus detected by DE-
MR, 50% (6 of 12) were not detected by cine-CMR and
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Figure 3 Thrombus Prevalence According to
Etiology and Severity of Myopathic Dysfunction
Thrombus prevalence (bar graph, left) was over 5-fold higher among patients
with ischemic cardiomyopathy as compared with those with nonischemic car-
diomyopathy (9.2% vs. 1.7%) despite nearly identical left ventricular ejection
fraction. When each group was stratified according to ejection fraction (line
graph, right), prevalence was higher in patients with ischemic disease for every
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Detection of LV Thrombus by DE-CMR July 8, 2008:148–578% (7 of 12) were not detected by echocardiography. A
ore recent study by Srichai et al. (14) compared CMR
ith echocardiography in a cohort of patients undergoing
V reconstruction surgery in whom surgical and/or
athology verification of thrombus was uniformly per-
ormed. This study reported that the sensitivity of trans-
horacic echocardiography was 23% and transesophageal
chocardiography was 40%, compared with 88% for
MR. However, because DE-CMR was interpreted in
onjunction with cine-CMR, this investigation did not
ermit conclusions to be made regarding the utility of
E-CMR alone for thrombus detection.
In the current study, validation of DE-CMR as an
ppropriate imaging standard for LV thrombus was ob-
ained via two means. First, all records were reviewed to
dentify patients who had direct inspection of the LV, and
athology specimens were carefully re-examined by a car-
iovascular pathologist blinded to imaging findings. With
his assessment, DE-CMR detected thrombus correctly
mong all 5 patients with pathology verified thrombus,
hereas cine-CMR detected thrombus in only 2. Second, to
btain additional evidence supporting the diagnosis of
hrombus among the overall study population, prospective
ollow-up was performed on all patients for clinical embolic
vents highly suggestive of thrombus within a pre-specified
-month window after CMR. These results also supported
E-CMR as a more appropriate reference standard than
ine-CMR. Patients with thrombus identified by DE-
MR had over a 7-fold higher rate of pathology and clinical
nd points than those without thrombus; cine-CMR pro-
ided lower discrimination between end points and no
dditional stratification once patients were grouped accord-
ng to presence or absence of thrombus by DE-CMR
Fig. 2).
On the other hand, the occurrence of CVA/TIA does not
rove the presence of LV thrombus because other sources
uch as carotid atherosclerosis could potentially explain
erebrovascular events. However, given that LV thrombus
as present on imaging, attributing CVA/TIA to this
ather than to other sources seems reasonable. Additionally,
ur follow-up was intentionally kept short to enhance the
emporal link between the presence of thrombus at the time
f imaging and clinical events. Although our follow-up
rotocol was tailored to relate clinical end points to imaging
ndings, absolute verification of the imaging diagnosis of
hrombus would require uniform pathology evaluation.
owever, we note that a population in which all patients
ould undergo pathology verification would be a highly
elected cohort that would not have allowed us to evaluate
hrombus prevalence and markers in a broad cross section of
atients with LV dysfunction, which was the primary aim of
his study.
The ability of DE-CMR to identify thrombus based on
issue characteristics rather than anatomical appearance
lone may explain why it provided improved thrombus
maging compared with cine-CMR. Because of its avascu- earity, thrombus has essentially no gadolinium uptake, and
his fact can be used to discern thrombus from myocardium
rrespective of its morphology or location. Although one
rior CMR study (27) reported that chronic organized
hrombus can show inhomogeneous gadolinium enhance-
ent, this study included only 5 patients with LV thrombus
nd used an older pulse sequence with poor temporal and
patial resolution and limited T1-weighting compared with
E-CMR. In our study, thrombus showed a uniform lack
f gadolinium enhancement. Likewise, Kirkpatrick et al.
11) using contrast perfusion echocardiography showed
bsence of contrast enhancement in cardiac thrombi, and
his consistent feature was found to greatly facilitate the
iagnosis of cardiac masses by differentiating thrombus
rom neoplasm. Moreover, because the primary distinguish-
ng characteristic is the presence or absence of contrast
ptake, cine-CMR after gadolinium infusion is likely superior
o nonenhanced cine-CMR for thrombus identification.
A particular advantage of DE-CMR is that it can
istinguish mural thrombus from immediately adjacent
yocardium. Our results show that although intracavitary
hrombi were typically detected by cine-CMR when large
nd generally missed when small, both small and large
ural thrombi often were undetected. For instance, cine-
MR had lower sensitivity for mural than intracavitary
hrombus despite a nearly 2-fold larger average size of mural
hrombus. Identification of mural thrombus is potentially of
linical importance. In prior studies, up to 40% of embolic
vents have occurred in patients with nonprotuberant or
mmobile thrombus (28).
One of the main aims of the present study was to examine
linical and imaging markers for the presence of LV
hrombus. As expected, a strong inverse relationship
etween LVEF and thrombus prevalence was found. In-
erestingly, multivariable analysis showed that increased
yocardial scarring, an additional parameter available from
E-CMR, was an independent risk factor for thrombus.
lthough prior studies of patients with myocardial infarc-
ion have observed that patients with larger infarcts have
reater likelihood for thrombus formation (29,30), the
echanism has always been assumed to be more extensive
ystolic dysfunction and/or remodeling, and not necessarily
he presence of scarring per se. Our results, however, show
hat both the amount of myocardial scarring and the extent
f systolic dysfunction are independent markers for throm-
us presence, with the 2 parameters providing additive
redictive value (Fig. 4C). For example, thrombus preva-
ence was often higher among patients with less extensive
ontractile dysfunction but with widespread myocardial
carring than those with extensive dysfunction but without
carring. The independent value of myocardial scarring may
n part explain the marked difference in thrombus preva-
ence according to cardiomyopathic etiology. For example,
atients with ischemic cardiomyopathy had over a 5-fold
igher prevalence of thrombus than patients with nonisch-
mic cardiomyopathy despite a nearly identical LVEF (Fig.
3
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July 8, 2008:148–57 Detection of LV Thrombus by DE-CMR). The increase in prevalence was paralleled by an increase
n scar burden, with scar size more than 3-fold higher
mong ischemic patients.
onclusions
n summary, this study shows that DE-CMR is a clinically
seful tool for the detection of LV thrombus. Anatomical
ssessment using cine-CMR was especially limited in pa-
ients with mural-type thrombus, among whom even large
hrombus was often missed. Additionally, myocardial scar as
dentified by DE-CMR was found to be a novel indepen-
ent risk factor for thrombus. Further investigation is
eeded to ascertain whether DE-CMR findings can be used
o guide anticoagulant therapy and improve clinical out-
omes among the growing population of patients with heart
ailure at risk for LV thrombus and related complications.
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